3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with gefitinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, H; Hu, MN; Li, JY; Miao, XK; Mou, LY; Xu, JJ; Yang, WL; Zhang, JY; Zhang, XW; Zhou, TX | 1 |
| Chen, M; Huang, F; Jiang, N; Jin, Q; Xu, X; Zheng, J | 1 |
2 other study(ies) available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and gefitinib
| Article | Year |
|---|---|
YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Endocytosis; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; Protein Transport; Proteolysis | 2020 |
HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib.
Topics: Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Hypoxia-Inducible Factor 1; Indazoles; Mutation; Phosphorylation; Proto-Oncogene Proteins c-met; Tumor Stem Cell Assay; Wound Healing | 2021 |